Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial

JAMA. 2021 Jul 27;326(4):355-357. doi: 10.1001/jama.2021.9380.

Abstract

This follow-up to the STOP-BPD randomized clinical trial, which investigated the efficacy and safety of systemic hydrocortisone treatment initiated 7 to 14 days after birth in ventilator-dependent, very preterm infants in the Netherlands and Belgium at 36 weeks’ postmenstrual age, examines the prespecified composite of death and neurodevelopmental impairment among these infants at 2 years’ corrected age.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchopulmonary Dysplasia / prevention & control
  • Child, Preschool
  • Follow-Up Studies
  • Humans
  • Hydrocortisone / therapeutic use*
  • Infant, Newborn
  • Infant, Premature*
  • Infant, Premature, Diseases / mortality*
  • Neurodevelopmental Disorders / epidemiology*
  • Respiration, Artificial

Substances

  • Hydrocortisone